Marival V Bermejo

List of Publications by Year
in descending order

135 papers	4,475 citations	147801 31 h-index	123424 61 g-index
164 all docs	164 docs citations	164 times ranked	4960 citing authors

#	Article	IF	Citations
1	Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling. AAPS Journal, 2022, 24, 17.	4.4	9
2	Integration of In Silico, In Vitro and In Situ Tools for the Preformulation and Characterization of a Novel Cardio-Neuroprotective Compound during the Early Stages of Drug Development. Pharmaceutics, 2022, 14, 182.	4.5	0
3	An Innovative Formulation Based on Nanostructured Lipid Carriers for Imatinib Delivery: Pre-Formulation, Cellular Uptake and Cytotoxicity Studies. Nanomaterials, 2022, 12, 250.	4.1	7
4	Exploring the Predictive Power of the In Situ Perfusion Technique towards Drug Absorption: Theory, Practice, and Applications. Molecular Pharmaceutics, 2022, 19, 749-762.	4.6	3
5	Effect of excipients on oral absorption process according to the different gastrointestinal segments. Expert Opinion on Drug Delivery, 2021, 18, 1005-1024.	5.0	8
6	Two-step in vitro-in vivo correlations: Deconvolution and convolution methods, which one gives the best predictability? Comparison with one-step approach. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 185-197.	4.3	6
7	An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics, 2021, 13, 507.	4.5	7
8	Eremantholide C from aerial parts of Lychnophora trichocarpha, as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination. DARU, Journal of Pharmaceutical Sciences, 2021, 29, 195-203.	2.0	1
9	One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products. Pharmaceutics, 2021, 13, 690.	4.5	2
10	In vitro model for predicting the access and distribution of drugs in the brain using hCMEC/D3 cells. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 120-126.	4.3	19
11	A differential equation based modelling approach to predict supersaturation and in vivo absorption from in vitro dissolution-absorption system (idas2) data. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 1-12.	4.3	9
12	Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat. Pharmaceutics, 2021, 13, 1402.	4.5	4
13	pH-Dependent Molecular Gate Mesoporous Microparticles for Biological Control of Giardia intestinalis. Pharmaceutics, 2021, 13, 94.	4.5	3
14	Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system. ADMET and DMPK, 2021, 9, 23-39.	2.1	7
15	New In Vitro Methodology for Kinetics Distribution Prediction in the Brain. An Additional Step towards an Animal-Free Approach. Animals, 2021, 11, 3521.	2.3	4
16	Report from the â€œ3rd International Symposium on BA/BE of Oral Drug Products: Biopharmaceutics meets Galenicsâ€• Journal of Drug Delivery Science and Technology, 2020, 56, 101274.	3.0	0
17	Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics, 2020, 12, 988.	4.5	12
18	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. European Journal of Pharmaceutical Sciences, 2020, 155, 105517.	4.0	18

#	Article	IF	Citations
19	New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy. International Journal of Molecular Sciences, 2020, 21, 6502.	4.1	43
20	Effect of Common Excipients on Intestinal Drug Absorption in Wistar Rats. Molecular Pharmaceutics, 2020, 17, 2310-2318.	4.6	8
21	Effect of thickener on disintegration, dissolution and permeability of common drug products for elderly patients. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 168-176.	4.3	6
22	Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-ColaÂ® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). Pharmaceutics, 2020, 12, 566.	4.5	8
23	In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium. Pharmaceutics, 2020, 12, 558.	4.5	7
24	Candesartan Cilexetil In Vitroâ€“In Vivo Correlation: Predictive Dissolution as a Development Tool. Pharmaceutics, 2020, 12, 633.	4.5	17
25	A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP. Pharmaceutics, 2020, 12, 74.	4.5	49
26	Oral controlled release dosage forms: dissolution versus diffusion. Expert Opinion on Drug Delivery, 2020, 17, 791-803.	5.0	13
27	Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019. Pharmaceutics, 2020, 12, 316.	4.5	17
28	Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System. Pharmaceutics, 2019, 11, 567.	4.5	27
29	â€œDevelopment of Fixed Dose Combination Productsâ€•Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy. AAPS Journal, 2019, 21, 75.	4.4	7
30	Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. Pharmaceutics, 2019, 11, 122.	4.5	17
31	Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: Potential in vivo implications. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 47-58.	4.3	27
32	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. International Journal of Molecular Sciences, 2019, 20, 1606.	4.1	32
33	Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products. Pharmaceutics, 2019, 11, 663.	4.5	10
34	Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug. International Journal of Pharmaceutics, 2019, 557, 36-42.	5.2	11
35	Impact on intestinal permeability of pediatric hyperosmolar formulations after dilution: Studies with rat perfusion method. International Journal of Pharmaceutics, 2019, 557, 154-161.	5.2	6
36	Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 174-183.	4.3	45

#	Article	IF	Citations
37	Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation. European Journal of Pharmaceutical Sciences, 2018, 119, 200-207.	4.0	2
38	Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model. AAPS Journal, 2018, 20, 57.	4.4	19
39	Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter. European Journal of Pharmaceutical Sciences, 2018, 117, 193-203.	4.0	5
40	Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Ratâ€"Biophysical Model and Predictions Based on Caco-2. Pharmaceutical Research, 2018, 35, 2.	3.5	23
41	Ionic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System. Biomacromolecules, 2018, 19, 1294-1304.	5.4	41
42	Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Journal of Pharmaceutical Sciences, 2018, 115, 258-269.	4.0	43
43	PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. European Journal of Pharmaceutical Sciences, 2018, 115, 119-125.	4.0	25
44	Giardiasis: Characteristics, Pathogenesis and New Insights About Treatment. Current Topics in Medicinal Chemistry, 2018, 18, 1287-1303.	2.1	58
45	Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs. Pharmaceutics, 2018, 10, 213.	4.5	4
46	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€"Part 2: Fed State. Molecular Pharmaceutics, 2018, 15, 5468-5478.	4.6	12
47	Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonateâ€"CO₂ Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance. Molecular Pharmaceutics, 2018, 15, 5291-5301.	4.6	23
48	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€"Part 1: Fasted State Conditions. Molecular Pharmaceutics, 2018, 15, 5454-5467.	4.6	21
49	In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance. AAPS Journal, 2018, 20, 100.	4.4	7
50	Determination of intestinal permeability using in situ perfusion model in rats: Challenges and advantages to BCS classification applied to digoxin. International Journal of Pharmaceutics, 2018, 551, 148-157.	5.2	18
51	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 162-174.	4.3	24
52	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded â€˜21st Century BA/BEâ€™ project. International Journal of Pharmaceutics, 2018, 548, 120-127.	5.2	41
53	Preclinical models for colonic absorption, application to controlled release formulation development. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 130, 247-259.	4.3	10
54	Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and iorÂ®EPOCIM in New Zealand rabbits. European Journal of Pharmaceutical Sciences, 2018, 120, 123-132.	4.0	0

#	Article	IF	Citations
55	In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. Molecular Pharmaceutics, 2018, 15, 2307-2315.	4.6	26
56	Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. British Journal of Clinical Pharmacology, 2018, 84, 2231-2241.	2.4	18
57	Summary of the In Vivo Predictive Dissolution (iPD) - Oral Drug Delivery (ODD) Conference 2018. Dissolution Technologies, 2018, 25, 50-53.	0.6	2
58	Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B Coculture Models To Predict Intestinal and Colonic Permeability Compared to Caco-2 Monoculture. Molecular Pharmaceutics, 2017, 14, 1264-1270.	4.6	123
59	Investigating drug absorption from the colon: Single-pass vs. Doluisio approaches to in-situ rat large-intestinal perfusion. International Journal of Pharmaceutics, 2017, 527, 135-141.	5.2	28
60	Gated Mesoporous Silica Nanocarriers for a â€œTwo-Stepâ€•Targeted System to Colonic Tissue. Molecular Pharmaceutics, 2017, 14, 4442-4453.	4.6	18
61	Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs. Molecular Pharmaceutics, 2017, 14, 4281-4294.	4.6	94
62	Comparison of segmental-dependent permeability in human and in situ perfusion model in rat. European Journal of Pharmaceutical Sciences, 2017, 107, 191-196.	4.0	21
63	Enhancing Oral Absorption of Î²-Lapachone: Progress Till Date. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 1-10.	1.6	6
64	Evaluation of the intestinal permeability of rosemary (Rosmarinus officinalis L.) extract polyphenols and terpenoids in Caco-2 cell monolayers. PLoS ONE, 2017, 12, e0172063.	2.5	35
65	IVIVC approach based on carbamazepine bioequivalence studies combination. Die Pharmazie, 2017, 72, 449-455.	0.5	12
66	Segmental-dependent permeability throughout the small intestine following oral drug administration: Single-pass vs. Doluisio approach to in-situ rat perfusion. International Journal of Pharmaceutics, 2016, 515, 201-208.	5.2	46
67	Development of an ion-pair to improve the colon permeability of a low permeability drug: Atenolol. European Journal of Pharmaceutical Sciences, 2016, 93, 334-340.	4.0	17
68	Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles. AAPS Journal, 2016, 18, 1550-1561.	4.4	18
69	Population pharmacokinetic model of lithium and drug compliance assessment. European Neuropsychopharmacology, 2016, 26, 1868-1876.	0.7	8
70	Intestinal Permeability of Î²-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 795-806.	1.6	7
71	Exploring different strategies for imbalanced ADME data problem: case study on Caco-2 permeability modeling. Molecular Diversity, 2016, 20, 93-109.	3.9	11
72	Permeability Study of Polyphenols Derived from a Phenolic-Enriched Hibiscus sabdariffa Extract by UHPLC-ESI-UHR-Qq-TOF-MS. International Journal of Molecular Sciences, 2015, 16, 18396-18411.	4.1	28

#	Article	IF	Citations
73	In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approaches. International Journal of Pharmaceutics, 2015, 480, 1-7.	5.2	63
74	In vitroâ€“in vivocorrelations: general concepts, methodologies and regulatory applications. Drug Development and Industrial Pharmacy, 2015, 41, 1935-1947.	2.0	36
75	Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. Journal of Medicinal Chemistry, 2015, 58, 5825-5841.	6.4	88
76	Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients. European Journal of Pharmaceutical Sciences, 2015, 73, 57-63.	4.0	2
77	Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. European Journal of Pharmaceutical Sciences, 2015, 74, 86-94.	4.0	6
78	In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model. Journal of Pharmaceutical Sciences, 2015, 104, 3136-3145.	3.3	57
79	Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. Molecular Pharmaceutics, 2015, 12, 3167-3174.	4.6	26
80	Drug gastrointestinal absorption in rat: Strain and gender differences. European Journal of Pharmaceutical Sciences, 2015, 78, 198-203.	4.0	15
81	Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors. British Journal of Pharmacology, 2015, 172, 829-840.	5.4	17
82	Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers. Journal of Pharmacological and Toxicological Methods, 2015, 71, 21-32.	0.7	31
83	A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. European Journal of Medicinal Chemistry, 2014, 83, 366-373.	5.5	22
84	Modified Nonsink Equation for Permeability Estimation in Cell Monolayers: Comparison with Standard Methods. Molecular Pharmaceutics, 2014, 11, 1403-1414.	4.6	18
85	Validation of phenol red versus gravimetric method for water reabsorption correction and study of gender differences in Doluisioâ€™s absorption technique. European Journal of Pharmaceutical Sciences, 2014, 62, 105-110.	4.0	23
86	Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. Xenobiotica, 2013, 43, 745-754.	1.1	5
87	Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Bloodâ€“Brain Barrier. Molecular Pharmaceutics, 2013, 10, 3822-3831.	4.6	19
88	Purely in Silico BCS Classification: Science Based Quality Standards for the Worldâ€™s Drugs. Molecular Pharmaceutics, 2013, 10, 4378-4390.	4.6	66
89	Ion-pair strategy for enabling amifostine oral absorption: Rat in situ and in vivo experiments. European Journal of Pharmaceutical Sciences, 2013, 49, 499-504.	4.0	28
90	Hydrogels: an interesting strategy for smart drug delivery. Therapeutic Delivery, 2013, 4, 157-160.	2.2	22

#	Article	IF	Citations
91	The Use of Ruleâ€Based and QSPR Approaches in ADME Profiling: A Case Study on Cacoâ€2 Permeability. Molecular Informatics, 2013, 32, 459-479.	2.5	42
92	Provisional Classification and in Silico Study of Biopharmaceutical System Based on Caco-2 Cell Permeability and Dose Number. Molecular Pharmaceutics, 2013, 10, 2445-2461.	4.6	78
93	Semisynthesis, Cytotoxic Activity, and Oral Availability of New Lipophilic 9-Substituted Camptothecin Derivatives. ACS Medicinal Chemistry Letters, 2013, 4, 651-655.	2.8	17
94	QSPR in Oral Bioavailability: Specificity or Integrality?. Mini-Reviews in Medicinal Chemistry, 2012, 12, 534-550.	2.4	20
95	A new mathematical approach for the estimation of the AUC and its variability under different experimental designs in preclinical studies. Pharmaceutical Statistics, 2012, 11, 14-23.	1.3	5
96	In vitroâ€“in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 65-75.	1.6	15
97	Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as bloodâ€“brain barrier in vitro model. European Journal of Pharmaceutical Sciences, 2011, 42, 290-299.	4.0	29
98	In Silico Prediction of Cacoâ€2 Cell Permeability by a Classification QSAR Approach. Molecular Informatics, 2011, 30, 376-385.	2.5	76
99	Computer simulations for bioequivalence trials: Selection of analyte in BCS drugs with first-pass metabolism and two metabolic pathways. European Journal of Pharmaceutical Sciences, 2010, 41, 716-728.	4.0	14
100	An Exploratory Study of Two Caco-2 Cell Models for Oral Absorption: A Report on Their Within-laboratory and Between-laboratory Variability, and Their Predictive Capacity. ATLA Alternatives To Laboratory Animals, 2010, 38, 367-386.	1.0	23
101	Drug penetration across the bloodâ€“brain barrier: an overview. Therapeutic Delivery, 2010, 1, 535-562.	2.2	24
102	Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Linear kinetics (I). European Journal of Pharmaceutical Sciences, 2009, 36, 137-146.	4.0	22
103	Unique pharmacology of KAR-2, a potential anti-cancer agent: Absorption modelling and selective mitotic spindle targeting. European Journal of Pharmaceutical Sciences, 2009, 36, 11-19.	4.0	8
104	Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics. European Journal of Pharmaceutical Sciences, 2009, 36, 147-156.	4.0	18
105	Pharmacokinetics in Drug Discovery. Journal of Pharmaceutical Sciences, 2008, 97, 654-690.	3.3	116
106	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir. Journal of Pharmaceutical Sciences, 2008, 97, 5061-5073.	3.3	79
107	Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2008, 366, 3599-3617.	3.4	13
108	Bias in Estimation of Transporter Kinetic Parameters from Overexpression Systems: Interplay of Transporter Expression Level and Substrate Affinity. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 133-144.	2.5	32

#	Article	IF	Citations
109	In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation within vitro results. Biopharmaceutics and Drug Disposition, 2007, 28, 229-239.	1.9	29
110	A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan. Molecular Pharmaceutics, 2006, 3, 631-643.	4.6	493
111	Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin. International Journal of Pharmaceutics, 2006, 307, 33-41.	5.2	20
112	A topological substructural approach for the prediction of P-glycoprotein substrates. Journal of Pharmaceutical Sciences, 2006, 95, 589-606.	3.3	53
113	Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. Xenobiotica, 2005, 35, 1067-1088.	1.1	35
114	Kinetic modelling of the intestinal transport of sarafloxacin. Studiesin situin rat andin vitroin Caco-2 cells. Journal of Drug Targeting, 2005, 13, 199-212.	4.4	23
115	PAMPAâ€"a drug absorption in vitro model. European Journal of Pharmaceutical Sciences, 2004, 21, 429-441.	4.0	187
116	TOPSâ€MODE Approach for the Prediction of Bloodâ€"Brain Barrier Permeation. Journal of Pharmaceutical Sciences, 2004, 93, 1701-1717.	3.3	40
117	In silico prediction of central nervous system activity of compounds. Identification of potential pharmacophores by the TOPSâ€"MODE approach. Bioorganic and Medicinal Chemistry, 2004, 12, 5833-5843.	3.0	21
118	A topological sub-structural approach for predicting human intestinal absorption of drugs. European Journal of Medicinal Chemistry, 2004, 39, 905-916.	5.5	60
119	Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Molecular Pharmaceutics, 2004, 1, 85-96.	4.6	691
120	Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 55, 241-246.	4.3	32
121	A topological-substructural molecular design (TOPS-MODE) approach to determining pharmacokinetics and pharmacological properties of 6-fluoroquinolone derivatives. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 197-206.	4.3	16
122	Kinetic Modeling of Triamterene Intestinal Absorption and its Inhibition by Folic Acid and Methotrexate. Journal of Drug Targeting, 2003, 11, 215-223.	4.4	9
123	A novel approach to determining physicochemical and absorption properties of 6-fluoroquinolone derivatives: experimental assessment. European Journal of Pharmaceutics and Biopharmaceutics, 2002, 53, 317-325.	4.3	45
124	Intrinsic Absolute Bioavailability Prediction in Rats Based on In Situ Absorption Rate Constants and/or In Vitro Partition Coefficients: 6â€Fluoroquinolones. Journal of Pharmaceutical Sciences, 2000, 89, 1395-1403.	3.3	28
125	Effects of Ethanol on Intestinal Absorption of Drugs: In Situ Studies with Ciprofloxacin Analogs in Acute and Chronic Alcohol-Fed Rats. Alcoholism: Clinical and Experimental Research, 1999, 23, 1403-1408.	2.4	13
126	Validation of a biophysical drug absorption model by the PATQSAR system. Journal of Pharmaceutical Sciences, 1999, 88, 398-405.	3.3	39

#	Article	IF	Citations
127	Pharmacokinetics, bioavailability and absorption of flumequine in the rat. European Journal of Pharmaceutics and Biopharmaceutics, 1999, 48, 253-258.	4.3	20
128	Compared effects of synthetic and natural bile acid surfactant on xenobiotic absorption. II. Studies with sodium glycocholate to confirm a hypothesis. International Journal of Pharmaceutics, 1994, 101, 209-217.	5.2	12
129	Compared effects of synthetic and natural bile acid surfactants on xenobiotic absorption. III. studies with mixed micelles. International Journal of Pharmaceutics, 1994, 107, 159-166.	5.2	7
130	Absorption-partition relationships for true homologous series of xenobiotics as a possible approach to study mechanisms of surfactants in absorption. IV. Phenylacetic acid derivatives and anionic surfactants. International Journal of Pharmaceutics, 1992, 79, 135-140.	5.2	8
131	Compared effects of synthetic and natural bile acid surfactants on xenobiotic absorption I. Studies with polysorbate and taurocholate in rat colon. International Journal of Pharmaceutics, 1991, 69, 221-231.	5.2	25
132	Gastric absorption of acidic xenobiotics in the rat: Biophysical interpretation of an apparently atypical behaviour. International Journal of Pharmaceutics, 1990, 64, 127-138.	5.2	21
133	How and Where Are Drugs Absorbed?. , 0, , 249-280.		3
134	Computer Simulations as a Tool for Optimizing Bioequivalence Trials. , 0, , .		1
135	Towards computational prediction of Biopharmaceutics Classification System: a QSPR approach. , 0, , .		0